Introduction: There are lots of evidence supporting the interplay of genetic, immunologic, and environmental factors which promote pathological bone remodeling and joint damage in PsA. IL-27 was identified as a pro-inflammatory cytokine promoting the differentiation of T helper 1 cells, through STAT-1 signalling. IL-27 is a lymphokine that controls the survival, proliferation and effector characteristics of T and B cells. Moreover, IL-27 plays important roles in bone remodelling, where an imbalance between bone resorption and formation contributes to bone destruction in inflammatory arthritis. We analyzed the possible role of serum IL-27 levels in the pathogenesis of psoriatic arthritis.
Methods: 48 patients with PsA (32 male, 16 female) and 26 healthy controls were enrolled in this study. Duration of psoriasis ranged between 8 and 96 months and mean duration of arthritis at presentation was 12.9±10.4 months. Oligoarthritis was the commonest presentation. Serum IL-27 levels were determined by ELISA.
Results: The mean serum IL-27 levels were 28,3±9.1 pg/ml in healthy controls, 63,5±27.1 pg/ml in patients with PsA. Serum IL-27 levels in patients with PsA were significantly higher than in healthy controls (p<0.001). Serum IL-27 levels in patients with PsA were similar in all groups. In patients with PsA, there are statistically significant correlati─▒on between serum IL-27 and serum ESR and CRP levels (r=0,504, p<0.01 and r=0.522, p<0.01 respectively).
Conclusions: We demonstrated that serum IL-27 levels were significantly elevated in patients with PsA. This result suggest that IL-27 may play a significant role of in the pathogenesis of PsA.